MedTrace Logo

A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer

NCT02459457 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 321

Last updated 2022-02-09

No results posted yet for this study

Summary

The purpose of this study is to determined the best scheme in paclitaxel and cisplatin，paclitaxel and fluorouracil，paclitaxel and carboplatin concurrent with radiotherapy for patients with local advanced esophageal Squamous Cell Carcinoma.

Conditions

  • Stage III Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Paclitaxel and Cisplatin

patients get Paclitaxel and Cisplatin according to protocol

DRUG

Paclitaxel and Fluorouracil

patients get Paclitaxel and Fluorouracil according to protocol

DRUG

Paclitaxel and Carboplatin

patients get Paclitaxel and Carboplatin according to protocol

RADIATION

Radiotherapy

1.8Gy/d, d1-5/week, 34Fx

Sponsors & Collaborators

  • Huadong Hospital

    collaborator OTHER

  • Wuxi No. 4 People's Hospital

    collaborator OTHER

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    collaborator OTHER

  • Jiangxi Provincial Cancer Hospital

    collaborator OTHER

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • Gansu Cancer Hospital

    collaborator OTHER

  • Fudan University

    lead OTHER

Principal Investigators

  • Kuaile Zhao, MD · +86 18017312534

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2020-07-01
Completion
2022-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459457 on ClinicalTrials.gov